Neurocrine Biosciences (NBIX) EPS (Basic) (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported EPS (Basic) for 17 consecutive years, with $1.43 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EPS (Basic) rose 31.67% year-over-year to $1.43; the trailing twelve-month figure through Jun 2026 stood at $6.99 (up 98.54% YoY), and the FY2025 full-year result was $4.81, up 41.5% from the prior year.
• EPS (Basic) eased to $1.43 in Q2 2026 per NBIX's latest filing, from $1.97 in the prior quarter.
• Across five years, EPS (Basic) topped out at $2.11 in Q3 2025 and bottomed at -$0.79 in Q1 2023.
• Historically, EPS (Basic) has averaged $0.88 across 5 years, with a median of $0.95 in 2022.
• The sharpest annual moves came in 2023 and 2026: EPS (Basic) sank 640.86% in 2023, then soared 2385.12% in 2026.
• Over 5 years, EPS (Basic) stood at $0.93 in 2022, then jumped by 62.73% to $1.51 in 2023, then tumbled by 32.07% to $1.03 in 2024, then jumped by 50.43% to $1.54 in 2025, then fell by 7.45% to $1.43 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered $1.43, $1.97, and $1.54 for Q2 2026, Q1 2026, and Q4 2025 respectively.